Understanding the New BMC Public Health Study on HIV Trends

The latest research published in BMC Public Health on March 3, 2026, provides a comprehensive trend analysis of key HIV indicators in South Africa from 2011 to 2023, leveraging data from Population-based HIV Impact Assessments (PHIA). These surveys offer nationally representative insights into HIV prevalence, incidence, diagnosis rates, treatment coverage, and viral suppression at the population level. South Africa, home to approximately 8 million people living with HIV (PLHIV) as of 2024, continues to grapple with the world's largest HIV epidemic, making this analysis timely and critical.

Conducted in collaboration with PEPFAR and local health authorities, PHIA surveys involve household-based testing and biomarker analysis, providing unbiased estimates unlike clinic-based data. The study synthesizes data from multiple rounds, including South Africa's SABSSM surveys (akin to PHIA), revealing steady progress punctuated by COVID-19 setbacks.

Historical Context: South Africa's HIV Epidemic Evolution

Since 2011, South Africa has transformed its HIV response through massive scale-up of antiretroviral therapy (ART). ART, which suppresses the virus to undetectable levels, prevents transmission and disease progression. In 2011, only about 20% of PLHIV knew their status, with treatment coverage below 30%. By 2022, these figures had soared, aligning with UNAIDS 95-95-95 targets: 95% diagnosed, 95% on treatment, 95% virally suppressed.

The epidemic disproportionately affects women, with adult prevalence (15-49 years) around 19-20% in recent years, peaking in KwaZulu-Natal at nearly 25%. New infections dropped 44% from 2010 levels, from higher rates to about 150,000 annually by 2022.

Declining HIV Prevalence: A Positive Shift

The BMC paper highlights a gradual decline in HIV prevalence from roughly 14% in 2011 (SABSSM III) to 12.7% in 2022 (SABSSM VI), stabilizing around 13.9% by 2023. Among adults 15-49, prevalence fell from over 20% to 17.7% by 2025 projections, driven by reduced incidence and natural mortality offset by aging PLHIV.

Provincially, KwaZulu-Natal saw the sharpest drop due to high ART uptake, while Western Cape maintained lower rates at 11.2%. This trend underscores the impact of universal test-and-treat policies introduced in 2016.

HIV Incidence: Sustained Reductions with Caution

Incidence rates plummeted across provinces from 2010-2020, with KwaZulu-Natal achieving a 67% decline. Nationally, adult incidence dropped from ~2% to 0.73% by 2022. However, recent Thembisa models note slight upticks post-2022 due to testing disruptions.

• Young women (15-24): Highest risk group, but incidence fell >50% in 20-29 age band 2013-2018.
• Men: Slower declines, linked to lower testing.

The paper calls for targeted PrEP rollout, highest in Mpumalanga and KZN.

Diagnosis Rates: Nearing UNAIDS First 95%

Awareness rose from ~60% in 2011 to 93-95% by 2022-2024 across provinces. SABSSM VI reported 90% of PLHIV aged 15+ knew their status, uniform progress reflecting expanded testing.Explore research roles advancing HIV diagnostics.

ART Coverage: Gaps Persist Despite Scale-Up

Treatment coverage climbed from <30% to 77-81% nationally, highest in KZN (85%), lowest in Limpopo (68%). Thembisa estimates 5.7 million on ART by 2022, but only 78% of diagnosed on meds. Barriers include stigma, access in rural areas.

Viral Suppression: Peak and Post-COVID Dip

Suppression peaked at 71% men/79% women in 2022, meeting third 95% in most provinces (90-95%). A 2023 decline attributed to COVID-linked stockouts and clinic closures. CD4 counts rose median 396 to 465 cells/µL 2013-2023.

Provincial Disparities and Vulnerable Groups

KZN leads progress but highest prevalence; Western Cape lowest incidence. Young women, key populations (MSM, sex workers) lag. Adolescent girls 15-24: 6.9% prevalence vs 3.5% boys.

• UNAIDS data dashboard for global comparisons.

COVID-19 Disruptions: A Setback Analyzed

Lockdowns reduced testing by ~40%, causing diagnosis/treatment gaps. Viral suppression dipped, incidence stalled. Recovery via differentiated service delivery (DSD) models like community ART clubs.

Policy Implications and 95-95-95 Progress

South Africa nears first/third 95s but lags second. NSP 2023-2028 emphasizes PrEP, DSD, integration with TB/STIs. Investments: R54bn NSFAS-like for HIV? No, but PEPFAR/GEF funding key.

Future Outlook: Pathways to Epidemic Control

Projections: Incidence <1/1000 by 2055 if trends hold. Needed: Scale long-acting PrEP (lenacapavir trials), address inequities, sustain funding amid US cuts. Role of universities in research/vaccines.

For academics, opportunities abound in HIV modeling, epidemiology. Check South Africa university jobs or research positions.

Photo by The 77 Human Needs System on Unsplash

Stakeholder Perspectives and Actionable Insights

Experts like Thembisa creators urge inter-provincial learning from KZN. HSRC: Focus AGYW prevention. Communities advocate stigma reduction. Steps: Enhance male circumcision (low WC), PrEP uptake.

Researchers can contribute via research assistant jobs, advancing PHIA-like studies.